Cargando…

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

BACKGROUND: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acquired pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in hospitalized CAP patients. The aim of the present st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaseanu, Cristina, Milutinovic, Slobodan, Calistru, Petre I, Strausz, Janos, Zolubas, Marius, Chernyak, Valeriy, Dartois, Nathalie, Castaing, Nathalie, Gandjini, Hassan, Cooper, C Angel
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753558/ https://www.ncbi.nlm.nih.gov/pubmed/19740418 http://dx.doi.org/10.1186/1471-2466-9-44

Ejemplares similares

Tigecycline Versus Levofloxacin in Hospitalized Patients With Community-Acquired Pneumonia: An Analysis of Risk Factors
por: Dartois, Nathalie, et al.
Publicado: (2013)

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin
por: Ramirez, Julio A, et al.
Publicado: (2012)

Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
por: Endimiani, Andrea, et al.
Publicado: (2005)

Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia
por: Townsend, Mary L, et al.
Publicado: (2011)

Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Madadi-Goli, Nahid, et al.
Publicado: (2017)

Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease
por: Torres, Antoni, et al.
Publicado: (2015)

Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
por: Zhou, Yangang, et al.
Publicado: (2019)

Role of PatAB Transporter in Efflux of Levofloxacin in Streptococcus pneumoniae
por: Amblar, Mónica, et al.
Publicado: (2022)

Teicoplanin – Tigecycline Combination Shows Synergy Against Mycobacterium abscessus
por: Aziz, Dinah B., et al.
Publicado: (2018)

Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniae
por: He, Fang, et al.
Publicado: (2015)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study
por: Yadegarynia, Davood, et al.
Publicado: (2022)

Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii
por: Liu, Ben, et al.
Publicado: (2020)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae
por: Sun, Lilan, et al.
Publicado: (2022)

Severe Hyponatremia due to Levofloxacin Treatment for Pseudomonas aeruginosa Community-Acquired Pneumonia in a Patient with Oropharyngeal Cancer
por: Mocan, Mihaela, et al.
Publicado: (2016)

In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for hospital acquired pneumonia
por: Petersen, Peter J., et al.
Publicado: (2010)

Antimicrobial Effects of Minocycline, Tigecycline, Ciprofloxacin, and Levofloxacin against Elizabethkingia anophelis Using In Vitro Time-Kill Assays and In Vivo Zebrafish Animal Models
por: Lin, Jiun-Nong, et al.
Publicado: (2021)

A mild form of a Stevens-Johnson syndrome to ciprofloxacin
por: Madalan, Elena, et al.
Publicado: (2014)

Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
por: Noreddin, Ayman M, et al.
Publicado: (2011)

Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient
por: Al-Qadheeb, Nada S., et al.
Publicado: (2010)

Clinical Efficacy, Antibiotic Resistance Genes, Virulence Factors and Outcome of Hospital-Acquired Pneumonia Induced by Klebsiella pneumoniae Carbapenemase 2-Producing with Tigecycline Treatment in the ICU
por: Bai, Xiang-Rong, et al.
Publicado: (2022)

Comparison of levofloxacin (L) and cefotaxime (C) combined with ofloxacin (O) for treatment of severe community-acquired pneumonia (CAP) in the intensive care unit
por: Leroy, O, et al.
Publicado: (2004)

The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials
por: Chang, Shen-Peng, et al.
Publicado: (2019)

Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
por: Khan, Alina S, et al.
Publicado: (2023)

Extended-spectrum β-lactamase Klebsiella pneumoniae meningitis treated with tigecycline
por: Wadi, Jamal Ahmad, et al.
Publicado: (2009)

Tigecycline Resistant Klebsiella pneumoniae Isolated from Austrian River Water
por: Hladicz, Alexander, et al.
Publicado: (2017)

Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach
por: Pienaar, Elsje, et al.
Publicado: (2017)

The Rapid Emergence of Tigecycline Resistance in bla(KPC–2) Harboring Klebsiella pneumoniae, as Mediated in Vivo by Mutation in tetA During Tigecycline Treatment
por: Du, Xiaoxing, et al.
Publicado: (2018)

Characterization of Tigecycline Resistance Among Tigecycline Non-susceptible Klebsiella pneumoniae Isolates From Humans, Food-Producing Animals, and in vitro Selection Assay
por: Moghimi, Mohaddeseh, et al.
Publicado: (2021)

Potential of Tetracycline Resistance Proteins To Evolve Tigecycline Resistance
por: Linkevicius, Marius, et al.
Publicado: (2016)

Evaluation of the Empiric use of Levofloxacin in Combination with Antipseudomonal Β-Lactams for the Treatment of Pneumonia
por: Bachna, Jon, et al.
Publicado: (2017)

Fitness of Escherichia coli mutants with reduced susceptibility to tigecycline
por: Linkevicius, Marius, et al.
Publicado: (2016)

Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan
por: Lin, Yi-Tsung, et al.
Publicado: (2014)

The Resistance Mechanism and Clonal Distribution of Tigecycline-Nonsusceptible Klebsiella pneumoniae Isolates in Korea
por: Ahn, Chulsoo, et al.
Publicado: (2016)

Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia
por: Lin, Shupeng, et al.
Publicado: (2018)

Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem‐resistant Klebsiella pneumoniae isolates
por: Park, Yumi, et al.
Publicado: (2020)

Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone: A case report
por: Yuan, Xin, et al.
Publicado: (2020)

Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection
por: Yu, Meiling, et al.
Publicado: (2023)

First Emergence of acrAB and oqxAB Mediated Tigecycline Resistance in Clinical Isolates of Klebsiella pneumoniae Pre-Dating the Use of Tigecycline in a Chinese Hospital
por: Zhong, Xue, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jfdqfnjr3mm357s7k4gpribci2